IDH2 and central nervous system cancer: The wide overlap in the survival range of grades 2 and 3 IDH-mutant glioma patients appears in part due to the subjective nature of the histological grading of IDH-mutant tumors: There are no sharp and objective criteria distinguishing grade 2 form grade 3 tumors.